2016 Archived Content
Monday, October 31, 6:00-9:00 pm
(SC1) Introduction to High-Content Phenotypic Screening
The ever-increasing demand for improved productivity in research through the generation of robust analysis outputs has driven both the development and deployment of automated high-content analysis (HCA) and phenotypic cell-based approaches to drug discovery. In contrast to the more traditional cellular analysis and target-based approaches, here the researcher is able to evaluate the efficacy of potential therapeutics by monitoring the physiological state of cells through the simultaneous analysis of multiple cellular parameters in the context of an intact biological system. This course will cover the key features of HCS/A technologies and the best approaches to using these technologies for phenotypic cell-based screening.
Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging Queensland (TCIQ), Institute of Health Biomedical Innovation, Queensland University of Technology
Who should attend?
This course has been developed to introduce and facilitate scientists who are either moving into the field or who are interested in further developing new phenotypic discovery applications and tools for use with these technologies.
(i) An introduction to HCA technologies
(ii) Advanced cell-based models for use with HCA
(iii) Working examples of the phenotypic screening approach and future directions
(iv) Group Discussion and Q&A
- Develop a familiarity of the basics of HCS/A technologies
- Gain an understanding of the capabilities of this technology
- Learn of the latest developments in cell-based models for use in this field
- Get a better understanding of the key principles of assay design and development for phenotypic screening
Tuesday, November 1, 6:00-9:00 pm
(SC2) Expert ThinkTank: How to Meet the Need for Physiologically Relevant Assays
It used to be adequate to build target-specific and robust assays to drive lead optimization. These assays were relatively inexpensive and reliable and could be counted on to provide chemists with usable results. However, with time, it has become apparent that it is not enough to be robust and target specific. To build therapies for patients, we need to have assays that are more predictive of patient outcome. The current buzz words are “physiologically relevant assays.” This session will explore the need for physiologically relevant assays and explore the ways that we can achieve this endpoint.
Discussion topics include:
- What is the driver for more physiologically-relevant assays?
- What is the current state of the art?
- Advantages and shortcomings of the current technologies
- What is needed to build more physiologically-relevant assays? What are the requirements for cells, assay systems and budget?
- What are the compromises that can be allowed when building tools?
- What would be the ideal outcome and timelines?
Lisa Minor, Ph.D., President, In Vitro Strategies, LLC
Paul Andrews, Ph.D., Director of Operations, National Phenotypic Screening Centre, University of Dundee; Director and Owner, Stem Cell Solutions
Geoffrey A. Bartholomeusz, Ph.D., Associate Professor/Director, Target Identification and Validation Program, University of Texas MD Anderson Cancer Center
Neil Carragher, Ph.D., Professor, Drug Discovery, Insitute of Genetics and Molecular Medicine, University of Edinburgh
Edna Cukierman, Ph.D., Associate Professor, Cancer Biology Program, Fox Chase Cancer Center
Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging Queensland, Queensland University of Technology
Xavier Gidrol, Ph.D., Lab Director, CEA/INSERM/UGA
Edward Kelly, Ph.D., Associate Professor, Pharmaceutics, University of Washington, Seattle
Mark Mercola, Ph.D., Professor, Department of Medicine and Cardiovascular Institute, Stanford University School of Medicine
Matthias Nees, Ph.D., Coordinator, HCS Lab, Turku Science Park/Finland
Bonnie Sloane, Ph.D., Distinguished Professor, Pharmacology, Wayne State University
Fabien Vincent, Ph.D., Associate Research Fellow, Assay Development and Pharmacology, Hit Discovery and Lead Profiling, Pfizer Global R&D
*Separate registration required.